0
0
SILVER SPRING, Md. – In a move set to reshape the treatment landscape for blood cancer, the U.S. Food and Drug Administration (FDA) approved a powerful new combination therapy for patients with relapsed multiple myeloma on March 5, 2026. The agency greenlit the use of Tecvayli (teclistamab) in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adults who have seen their cancer return after at least one prior line of therapy.
The approval—issued just 55 days after the application was filed—converts Tecvayli’s previous “accelerated” status to a traditional approval. More importantly, it moves this advanced immunotherapy from a “last-resort” treatment into the second line of care, offering a potent new option for the estimated 40% of patients whose disease returns early in their journey.
A “New Era” in Myeloma Care
Multiple myeloma is the third most common blood cancer in the U.S., characterized by the malignant proliferation of plasma cells in the bone marrow. While treatments have improved, the disease remains incurable and highly prone to relapse.
“This new treatment option can redefine how we approach relapsed/refractory treatment by giving healthcare providers a regimen with significant improvement in survival and a well-characterized safety profile,” said Dr. Luciano J. Costa, Professor of Multiple Myeloma at the University of Alabama at Birmingham and the study’s principal investigator. “Using this regimen as early as the second line is critical because patients often become less responsive to therapy with each subsequent relapse.”
Key Findings from the MajesTEC-3 Trial
The FDA decision was primarily driven by the MajesTEC-3 phase 3 trial, a study involving 587 patients. The trial compared the new Tecvayli-Darzalex combo against two current standard-of-care regimens. The results, published in The New England Journal of Medicine, demonstrated what researchers described as “unprecedented” efficacy:
-
Progression-Free Survival (PFS): The combination reduced the risk of cancer progression or death by 83% compared to standard treatments ($HR = 0.17$).
-
Three-Year Survival: At the three-year mark, 83.3% of patients on the new combo were still alive, compared to 65% in the control group.
-
Deep Responses: Nearly 82% of patients achieved a complete response (no detectable cancer), and 58% reached “minimal residual disease (MRD) negativity,” meaning no cancer cells were found even with highly sensitive testing.
How the Synergy Works
The success of the treatment lies in its “dual-targeting” approach. Multiple myeloma cells typically carry two specific markers: BCMA and CD38.
-
Tecvayli (a Bispecific T-cell Engager): Acts like a bridge. One arm grabs the BCMA on the cancer cell, while the other grabs the CD3 receptor on a healthy T-cell (the body’s natural “soldier” cell), forcing the immune system to attack the cancer directly.
-
Darzalex Faspro (a Monoclonal Antibody): Targets CD38. It not only kills cancer cells directly but also “primes” the environment, making the T-cells activated by Tecvayli even more effective.
Safety and Practical Considerations
While the efficacy is high, the treatment requires diligent medical management. The most common side effects observed in the trial were infections and “cytopenias” (low blood cell counts).
-
Infections: Nearly 96% of patients experienced some form of infection, though serious (Grade 3/4) infections declined significantly after the first six months once patients moved to monthly dosing and received protective immunoglobulin therapy.
-
Immune Reactions: 60.1% of patients experienced Cytokine Release Syndrome (CRS)—a rapid immune response that can cause fever and low blood pressure. However, all cases in the study were mild (Grade 1 or 2) and manageable.
-
REMS Program: Due to risks of neurological toxicity and CRS, the drug is administered through a specific safety program (REMS) to ensure clinics are equipped to handle reactions.
Shifting the Public Health Needle
For the roughly 36,000 Americans diagnosed with multiple myeloma annually, this approval represents a shift toward “off-the-shelf” immunotherapy. Unlike complex CAR-T therapies, which require weeks of laboratory manufacturing for each individual patient, this combination is ready to use and can be administered subcutaneously (under the skin) in community oncology centers.
“This is a pivotal milestone,” said Imran Khan, M.D., Ph.D., Vice President of U.S. Hematology Medical Affairs at Johnson & Johnson. “It moves us closer to the goal of turning multiple myeloma into a manageable, and perhaps one day, curable condition.”
Summary Table: Trial Outcomes at 3 Years
| Metric | Tecvayli + Darzalex | Standard Therapy |
| Risk Reduction (Death/Progression) | 83% Improvement | N/A |
| Overall Survival Rate | 83.3% | 65.0% |
| Complete Response Rate | 81.8% | 32.1% |
| MRD Negativity | 58.4% | 17.1% |
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
